Blu Mercury Conversations

Jeff Lindh
  • 0.0 (0)
  • MARKETING
  • UPDATED WEEKLY

Blu Mercury Conversations explores the critical challenges slowing down biotech, diagnostics, and life sciences companies — and how the best operators solve them. Each episode tackles a real execution problem: M&A integration bottlenecks, product management gaps, content strategy complexity, or marketing execution failures. We don't talk about what should happen. We talk about what actually works, drawn from decades of work with scaling biotech organizations. Hosted by Jeff Lindh, founder of Blu Mercury Consulting, this series is for biotech leaders, product teams, and operations executives navigating the messy middle of scaling — where strategy meets execution and plans meet reality. Topics include: M&A strategy • Data integration • Product management • Genomics operations • Life sciences marketing • Content strategy • Team execution • Biotech scaling Who this is for: VP Marketing, CMOs, Chief Medical Officers, VP Product, SVPs of Operations, and founders building in biotech, diagnostics, and life sciences who care about execution, not just vision. New episodes every Thursday.

Episodes

  1. Episode 3: Words and Pictures: How Early-Stage Biotech Learns to Speak Commercial

    1D AGO

    Episode 3: Words and Pictures: How Early-Stage Biotech Learns to Speak Commercial

    Scientific excellence doesn't communicate itself. Every early-stage biotech faces a structural gap between the science that builds the platform and the communication that makes it legible to investors, partners, and customers. Blu Mercury founder Jeff Lindh draws on his direct experience in life sciences content strategy and visual design to explore the two disciplines that bridge the science-commercial divide. What does a science narrative that your founding team trusts actually look like? What does visual design communicate beyond aesthetics — and why does it matter as much as what you write? This episode is a first-person account of what it takes to build a communication foundation in early-stage biotech — before the pressure moments that reveal its absence. For founders, CEOs, and commercial leads at early-stage biotech companies building discovery platforms, tools, or services. Keywords: life sciences content strategy, biotech communication, science narrative, visual design, early-stage biotech, commercialization, investor narrative, discovery technology, scientific credibility, biotech marketing

    14 min
  2. Episode 2 — From Vision to Roadmap: What Early-Stage Biotech Gets Wrong

    1D AGO

    Episode 2 — From Vision to Roadmap: What Early-Stage Biotech Gets Wrong

    You have the science. You have investors who believe in the vision. But do you have a roadmap — a real one? Not a slide. A structured plan that bridges scientific vision to actual operational execution. Blu Mercury founder Jeff Lindh explores why early-stage biotech startups consistently underestimate the roadmap problem — and what it looks like when a fractional PM consultant builds the product management foundation from scratch. Drawing on insights from Louise Baskin, a fractional PM consultant specializing in discovery technologies, services, and software for early-stage biotech, this episode breaks down the two layers every first roadmap needs: the strategic horizon and the tactical execution plan. For founders, CEOs, and commercial leads at early-stage biotech companies building discovery platforms, tools, or services. Keywords: product roadmap, early-stage biotech, fractional PM, startup execution, product management, discovery technology, biotech software, biotech services, biotech strategy, product development

    11 min
  3. Episode 1: M&A Data Integration — The Pre-Close Discovery Gap

    1D AGO

    Episode 1: M&A Data Integration — The Pre-Close Discovery Gap

    Most biotech acquisitions encounter data complexity post-close. The companies moving fastest conduct rigorous data discovery and mapping before closing. Learn why treating data integration as a due diligence issue — not a post-close technical problem — changes your entire integration timeline.

    8 min
  • 3 Episodes

About

Blu Mercury Conversations explores the critical challenges slowing down biotech, diagnostics, and life sciences companies — and how the best operators solve them. Each episode tackles a real execution problem: M&A integration bottlenecks, product management gaps, content strategy complexity, or marketing execution failures. We don't talk about what should happen. We talk about what actually works, drawn from decades of work with scaling biotech organizations. Hosted by Jeff Lindh, founder of Blu Mercury Consulting, this series is for biotech leaders, product teams, and operations executives navigating the messy middle of scaling — where strategy meets execution and plans meet reality. Topics include: M&A strategy • Data integration • Product management • Genomics operations • Life sciences marketing • Content strategy • Team execution • Biotech scaling Who this is for: VP Marketing, CMOs, Chief Medical Officers, VP Product, SVPs of Operations, and founders building in biotech, diagnostics, and life sciences who care about execution, not just vision. New episodes every Thursday.

Information

  • Creator
    Jeff Lindh
  • Years Active
    2K
  • Episodes
    3
  • Copyright
    © Acquavena LLC dba Blu Mercury